{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:20:44Z","timestamp":1772166044446,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The transition of Australia\u2019s National Cervical Screening Program from cytology to a molecular test for human papillomavirus (HPV) (locally referred to as the \u2018Renewal\u2019), including a longer five-year interval and older age at commencement, significantly impacted all sectors of program delivery. The Renewal had major implications for the roles and requirements of pathology laboratories providing services for the Program. This study aimed to understand the early impacts of the Renewal and its implementation on the pathology sector.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Semi-structured qualitative interviews were conducted with key stakeholders (N\u2009=\u200949) involved in the\n                      <jats:underline>ST<\/jats:underline>\n                      akeholder\n                      <jats:underline>O<\/jats:underline>\n                      pinions of\n                      <jats:underline>R<\/jats:underline>\n                      enewal\n                      <jats:underline>I<\/jats:underline>\n                      mplementation and\n                      <jats:underline>E<\/jats:underline>\n                      xperiences\n                      <jats:underline>S<\/jats:underline>\n                      tudy (STORIES), 11\u201320 months after the program transition. A subset of interviews (N\u2009=\u200924) that discussed the pathology sector were analysed using inductive thematic analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four overarching themes were identified: implementation enablers, challenges, missed opportunities, and possible improvements. Participants believed that the decision to transition to primary HPV screening was highly acceptable and evidence-based, but faced challenges due to impacts on laboratory infrastructure, resources, staffing, and finances. These challenges were compounded by unfamiliarity with new information technology (IT) systems and the new National Cancer Screening Register (\u2018Register\u2019) not being fully functional by the date of the program transition. The limited availability of self-collection and lack of standardised fields in pathology forms were identified as missed opportunities to improve equity in the Program. To improve implementation processes, participants suggested increased pathology sector involvement in planning was needed, along with more timely and transparent communication from the Government, and clearer clinical management guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The transition to primary HPV screening had a significant and multifaceted impact on the Australian pathology sector reflecting the magnitude and complexity of the Renewal. Strategies to support the pathology sector through effective change management, clear, timely, and transparent communication, as well as adequate funding sources will be critical for other countries planning to transition cervical screening programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-023-10040-6","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T16:28:27Z","timestamp":1696609707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The early impacts of primary HPV cervical screening implementation in Australia on the pathology sector: a qualitative study"],"prefix":"10.1186","volume":"23","author":[{"given":"Claire","family":"Bavor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia ML","family":"Brotherton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan A","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khic-Houy","family":"Prang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire M","family":"Zammit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe J","family":"Jennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhana","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy A","family":"Machalek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the STORIES team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"10040_CR1","unstructured":"Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding [Internet]. Sydney: Cancer Council Australia; 2017 [cited 2023 Apr 12]. Available from: https:\/\/www.cancer.org.au\/clinical-guidelines\/cervical-cancer-screening\/the-rationale-for-primary-hpv-screening."},{"issue":"8","key":"10040_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.5694\/mja16.00289","volume":"205","author":"M Smith","year":"2016","unstructured":"Smith M, Canfell K. Impact of the Australian National Cervical Screening Program in women of different ages. Med J Aust. 2016;205(8):359\u201364.","journal-title":"Med J Aust"},{"key":"10040_CR3","doi-asserted-by":"publisher","first-page":"a1754","DOI":"10.1136\/bmj.a1754","volume":"337","author":"J Dillner","year":"2008","unstructured":"Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint european cohort study. BMJ. 2008;337:a1754.","journal-title":"BMJ"},{"issue":"9916","key":"10040_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four european randomised controlled trials. The Lancet. 2014;383(9916):524\u201332.","journal-title":"The Lancet"},{"issue":"1","key":"10040_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12913-016-1375-9","volume":"16","author":"MA Smith","year":"2016","unstructured":"Smith MA, Gertig D, Hall M, Simms K, Lew JB, Malloy M, et al. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. BMC Health Serv Res. 2016;16(1):147.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10040_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/cncy.21642","volume":"124","author":"A Farnsworth","year":"2016","unstructured":"Farnsworth A. Cervical cancer screening in Australia: past and present. Cancer Cytopathol. 2016;124(4):231\u20134.","journal-title":"Cancer Cytopathol"},{"issue":"2","key":"10040_CR7","first-page":"31","volume":"71","author":"GA Lawrence","year":"2017","unstructured":"Lawrence GA, Frater TG. Change management in healthcare: managing paradigmatic change in the Australian National Cervical Screening Programme. N Z J Med Lab Sci. 2017;71(2):31\u201340.","journal-title":"N Z J Med Lab Sci"},{"key":"10040_CR8","unstructured":"The Royal College of Pathologists of Australasia. RCPA. [cited 2023 Apr 12]. Background\/History of NCSP. Available from: https:\/\/www.rcpa.edu.au\/Library\/Practising-Pathology\/NCSP\/Background."},{"issue":"7","key":"10040_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.31128\/AJGP-01-18-4471","volume":"47","author":"D Hawkes","year":"2018","unstructured":"Hawkes D. Human papillomavirus testing as part of the renewed National Cervical Screening Program. Aust J Gen Pract. 2018;47(7):412\u20134.","journal-title":"Aust J Gen Pract"},{"key":"10040_CR10","unstructured":"Australian Institute of Health and Welfare. National Cervical Screening Program monitoring report 2022 [Internet]. Canberra: AIHW. ; 2022 [cited 2023 Apr 12]. Available from: https:\/\/www.aihw.gov.au\/reports\/cancer-screening\/national-cervical-screening-program-monitoring-rep\/summary-1."},{"issue":"2","key":"10040_CR11","doi-asserted-by":"publisher","first-page":"2921914","DOI":"10.17061\/phrp2921914","volume":"29","author":"M Smith","year":"2019","unstructured":"Smith M, Hammond I, Saville M. Lessons from the renewal of the National Cervical Screening Program in Australia. Public Health Res Pract. 2019;29(2):2921914.","journal-title":"Public Health Res Pract"},{"key":"10040_CR12","unstructured":"National Pathology Accreditation Advisory Council. The requirements for laboratories reporting tests for the National Cervical Screening Program (Second edition 2019) [Internet]. Australian Government Department of Health; 2019 [cited 2023 Apr 13]. Available from: https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/npaac-cervical-screening."},{"issue":"23","key":"10040_CR13","doi-asserted-by":"publisher","first-page":"15776","DOI":"10.3390\/ijerph192315776","volume":"19","author":"CM Zammit","year":"2022","unstructured":"Zammit CM, Creagh NS, McDermott T, Smith MA, Machalek DA, Jennett CJ, et al. So, if she wasn\u2019t aware of it, then how would everybody else out there be aware of it?\u2014Key stakeholder perspectives on the initial implementation of self-collection in Australia\u2019s cervical screening program: a qualitative study. Int J Environ Res Public Health. 2022;19(23):15776.","journal-title":"Int J Environ Res Public Health"},{"key":"10040_CR14","doi-asserted-by":"crossref","unstructured":"Brotherton JML, McDermott T, Smith M, Machalek D, Shilling H, Prang K et al. Implementation of Australia\u2019s primary human papillomavirus (HPV) cervical screening program: the STakeholders opinions of Renewal implementation and Experiences Study. Prev Med Rep. 2023;102213.","DOI":"10.1016\/j.pmedr.2023.102213"},{"issue":"2","key":"10040_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","volume":"38","author":"E Proctor","year":"2011","unstructured":"Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011;38(2):65\u201376.","journal-title":"Adm Policy Ment Health"},{"issue":"2","key":"10040_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"5","key":"10040_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","volume":"26","author":"PJ Maver","year":"2020","unstructured":"Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26(5):579\u201383.","journal-title":"Clin Microbiol Infect"},{"key":"10040_CR18","unstructured":"Lew JB, Simms K, Smith M, Kang YJ, Xu X, Caruana M et al. MSAC Application number 1276: National Cervical Screening Program Renewal: Effectiveness modelling and economic evaluation in the Australian setting. 2014."},{"issue":"2","key":"10040_CR19","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1016\/S2468-2667(17)30007-5","volume":"2","author":"JB Lew","year":"2017","unstructured":"Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017;2(2):e96\u2013107.","journal-title":"Lancet Public Health"},{"key":"10040_CR20","volume-title":"Global strategy to accelerate the elimination of cervical cancer as a public health problem","author":"World Health Organisation","year":"2020","unstructured":"World Health Organisation. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020."},{"key":"10040_CR21","unstructured":"WHO guideline for screening. and treatment of cervical pre-cancer lesions for cervical cancer prevention [Internet]. Geneva; 2021 [cited 2023 May 17]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240030824."},{"issue":"8","key":"10040_CR22","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","volume":"10","author":"L Bruni","year":"2022","unstructured":"Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022;10(8):e1115\u201327.","journal-title":"Lancet Glob Health"},{"key":"10040_CR23","volume-title":"Cervical screening in Australia 2018","author":"Australian Institute of Health and Welfare","year":"2018","unstructured":"Australian Institute of Health and Welfare. Cervical screening in Australia 2018. Canberra: AIHW; 2018."},{"key":"10040_CR24","unstructured":"Services Australia. Requested Medicare items processed from January 2018 to December 2022 [Internet]. 2023. Available from: http:\/\/medicarestatistics.humanservices.gov.au\/statistics\/mbs_item.jsp."},{"issue":"3","key":"10040_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/hpja.280","volume":"31","author":"A Nagendiram","year":"2020","unstructured":"Nagendiram A, Bougher H, Banks J, Hall L, Heal C. Australian women\u2019s self-perceived barriers to participation in cervical cancer screening: a systematic review. Health Promot J Austr. 2020;31(3):343\u201353.","journal-title":"Health Promot J Austr"},{"key":"10040_CR26","first-page":"174550652210759","volume":"18","author":"NS Creagh","year":"2022","unstructured":"Creagh NS, Zammit C, Brotherton JM, Saville M, McDermott T, Nightingale C, et al. The experience of under-screened and never-screened participants using clinician-supported self-collection cervical screening within the Australian National Cervical Screening Program. Womens Health. 2022;18:17455065221075904.","journal-title":"Womens Health"},{"key":"10040_CR27","doi-asserted-by":"crossref","unstructured":"Creagh NS, Zammit C, Brotherton JM, Saville M, McDermott T, Nightingale C et al. Self-collection cervical screening in the renewed National Cervical Screening Program: a qualitative study. Med J Aust. 2021;215(8).","DOI":"10.5694\/mja2.51137"},{"key":"10040_CR28","doi-asserted-by":"crossref","unstructured":"Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;k4823.","DOI":"10.1136\/bmj.k4823"},{"key":"10040_CR29","doi-asserted-by":"crossref","unstructured":"Zammit C, Creagh N, Nightingale C, McDermott T, Saville M, Brotherton J, et al. I\u2019m a bit of a champion for it actually\u2019: qualitative insights into practitioner-supported self-collection cervical screening among early adopting victorian practitioners in Australia. Prim Health Care Res Dev. 2023 ed;24:e31.","DOI":"10.1017\/S1463423623000191"},{"issue":"1","key":"10040_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13012-019-0901-7","volume":"14","author":"SLE Roberts","year":"2019","unstructured":"Roberts SLE, Healey A, Sevdalis N. Use of health economic evaluation in the implementation and improvement science fields-a systematic literature review. Implement Sci IS. 2019;14(1):72.","journal-title":"Implement Sci IS"},{"key":"10040_CR31","doi-asserted-by":"crossref","unstructured":"Creagh NS, Boyd LAP, Bavor C, Zammit C, Saunders T, Oommen AM et al. Self-Collection Cervical Screening in the Asia-Pacific Region: a scoping review of implementation evidence. JCO Glob Oncol. 2023;(9):e2200297.","DOI":"10.1200\/GO.22.00297"},{"key":"10040_CR32","doi-asserted-by":"crossref","unstructured":"Saldana L, Ritzwoller DP, Campbell M, Block EP. Using economic evaluations in implementation science to increase transparency in costs and outcomes for organizational decision-makers. Implement Sci Commun. 2022;3(40).","DOI":"10.1186\/s43058-022-00295-1"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-10040-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-10040-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-10040-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T13:15:18Z","timestamp":1700486118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-10040-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10040"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-10040-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3012586\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The C4 CRE is a collaborative network being led by the Daffodil Centre (a joint venture between Cancer Council NSW and the University of Sydney), The Australian Centre for the Prevention of Cervical Cancer (ACPCC), the University of Melbourne and the Kirby Institute, University of New South Wales.JMLB is a former employee of ACPCC who has received contract funding from the Commonwealth Department of Health for work outside the current analysis relating to the National Cervical Screening Program. ACPCC has received equipment or supplies from Abbott, AusDiagnostics, BD, Cepheid, Copan, Hologic, Microbiologics, MicroBix, NRL, Qiagen, Rovers, Roche, and Seegene for research and validation studies. ACPCC has also received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana USA.MAS is an employee of Cancer Council NSW who has received contract funding from the Commonwealth Department of Health for work outside the current analysis relating to the National Cervical Screening Program.TM is a former employee of ACPCC who has received contract funding from the Commonwealth Department of Health for work outside the current analysis relating to the National Cervical Screening Program. ACPCC has received equipment or supplies from Abbott, AusDiagnostics, BD, Cepheid, Copan, Hologic, Microbiologics, MicroBix, NRL, Qiagen, Rovers, Roche, and Seegene for research and validation studies. ACPCC has also received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana USA.CEN is an employee of the University of Melbourne who has received contract funding from the Commonwealth Department of Health for work outside the current analysis relating to the National Cervical Screening Program.FS was involved in the STORIES project during her tenure at ACPCC until June 2019. She has since moved on to a new role at Telstra Health as an Epidemiologist. Telstra Health received contract funding from the Commonwealth Department of Health for managing the National Cancer Screening Register; however, this has had no impact of the conduct of the STORIES study.CJJ is an employee of Cancer Council NSW who has received contract funding from the Commonwealth Department of Health for work outside the current analysis relating to the National Cervical Screening Program.Members of the research team are employees of Cancer Council NSW (Authors MAS, CJJ) and ACPCC (Authors JMLB, TM) who were involved in the implementation of the Renewal and self-collection within the Renewal. In some cases, employees of ACPCC were invited to participate in the study. In instances where conflicts of interest were apparent between the participant and researcher, the interview was then performed by a research member without conflicts. All data was thematically analysed and deidentified with the wider study overseen by an Advisory Committee.CB has no competing interests to disclose.K-HP has no competing interests to disclose.NMR has no competing interests to disclose.CMZ has no competing interests to disclose.DAM has no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study obtained ethics approval from the University of Melbourne Human Research Ethics Committee (1852257). The study was conducted in accordance with relevant guidelines and regulations. All participants provided informed consent prior to participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable \u2013 this manuscript does not include any individual person\u2019s data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"1073"}}